Managing a malignant orocutaneous fistula: stem the tide with octreotide?
Gibson
S
S
Department of Palliative Care, Prince of Wales Hospital, Randwick, New South Wales, Australia.
Strutt
R
R
Chye
R
R
D000368:Aged; D003131:Combined Modality Therapy; D017577:Cutaneous Fistula / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D005500:Follow-Up Studies; D005598:Fractures, Spontaneous / Q000150:complications / Q000175:diagnosis; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008337:Mandibular Fractures / Q000150:complications / Q000175:diagnosis; D008545:Melanoma / Q000150:complications; D009059:Mouth Diseases / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D015282:Octreotide / Q000008:administration & dosage* / Q000009:adverse effects; D010019:Osteomyelitis / Q000150:complications; D012878:Skin Neoplasms / Q000150:complications; D016896:Treatment Outcome
D015282:Octreotide